论文部分内容阅读
目的 研究骨形成蛋白 ( bone morphogenetic protein,BMP)在骨肉瘤中的表达及其与肿瘤增殖活性的关系 ,并观察 BMP单抗体外对骨肉瘤细胞作用 ,为骨肉瘤的单抗治疗打下基础。方法 应用 BMP单抗和免疫组化方法检测骨肉瘤中 BMP蛋白的表达 ;并应用增殖细胞核抗原 ( proliferating cell nuclear antigen,PCNA)的单抗对骨肉瘤的增殖活性进行检测 ;体外实验观察 BMP单抗对骨肉瘤细胞 OS-73 2的作用。结果 2 4例标本中有 18例有 BMP蛋白的表达 ;有 BMP表达的骨肉瘤有较高的增殖活性 ;应用 BMP单抗体外可以对骨肉瘤细胞系 OS-73 2细胞产生生长抑制。结论 BMP有可能在肿瘤的发生和发展过程中起一定作用 ,可以作为估计骨肉瘤预后的参考指标 ,BMP单抗对骨肉瘤细胞的抑制作用为其临床应用于骨肉瘤的单抗治疗打下基础
Objective To study the expression of bone morphogenetic protein (BMP) in osteosarcoma and its relationship with tumor proliferation activity. To observe the effect of BMP monoclonal antibody on osteosarcoma in vitro and lay the foundation for the treatment of osteosarcoma with monoclonal antibody. Methods The expression of BMP protein in osteosarcoma was detected by BMP monoclonal antibody and immunohistochemistry. The proliferative activity of osteosarcoma was detected by using monoclonal antibody of proliferating cell nuclear antigen (PCNA). In vitro, BMP monoclonal antibody On osteosarcoma cell OS-73 2. RESULTS: BMP4 protein was expressed in 18 of 24 specimens. Osteosarcoma with BMP expression had higher proliferative activity. The growth inhibition of osteosarcoma cell line OS-73 2 cells was induced by BMP monoclonal antibody in vitro. Conclusion BMP may play a role in the occurrence and development of tumors and can be used as a reference index to evaluate the prognosis of osteosarcoma. The inhibition of BMP monoclonal antibody on osteosarcoma cells lays the foundation for its clinical application in the treatment of osteosarcoma monoclonal antibody